Last updated: 2 July 2021 at 11:07am EST

Sharon Tetlow Net Worth



Sharon Tetlow biography

Sharon Elizabeth Tetlow serves as Independent Director of the Company. She has served as Managing Partner of Potrero Hill Advisors since January 2016. Potrero Hill Advisors provides strategic and operational financial support to life science companies through its team of chief financial officers and controllers. Ms. Tetlow was previously the Managing Director of Danforth Advisors, a firm that provides service offerings for life science companies, from April 2013 to January 2016. She served as Chief Financial Officer of Pathwork Diagnostics, Inc., a biotechnology company, from 2011 to 2013. From 2005 to 2009, she served as Chief Financial Officer of Cell Genesys, Inc., a biotechnology company acquired by BioSante, another life sciences company. In connection with her role as managing partner of Potrero Hill Advisors, Ms. Tetlow and her team have led the finance function at numerous biotechnology companies. Ms. Tetlow received her B.A. in Psychology from University of Delaware and her M.B.A. from Stanford University.



How old is Sharon Tetlow?

Sharon Tetlow is 60, she's been the Independent Director of Catalyst Biosciences Inc since 2020. There are 7 older and 1 younger executives at Catalyst Biosciences Inc. The oldest executive at Catalyst Biosciences Inc is Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D., 67, who is the Consultant.

What's Sharon Tetlow's mailing address?

Sharon's mailing address filed with the SEC is C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Catalyst Biosciences Inc

Over the last 9 years, insiders at Catalyst Biosciences Inc have traded over $2,614,728 worth of Catalyst Biosciences Inc stock and bought 81,771 units worth $199,380 . The most active insiders traders include Jeff Himawan, James E Deerfield Mgmt L.P.... y Augustine Lawlor. On average, Catalyst Biosciences Inc executives and independent directors trade stock every 62 days with the average trade being worth of $3,315. The most recent stock trade was executed by Nassim Usman on 9 August 2022, trading 3,250 units of CBIO stock currently worth $1,528.



What does Catalyst Biosciences Inc do?

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.



What does Catalyst Biosciences Inc's logo look like?

Catalyst Biosciences Inc logo

Catalyst Biosciences Inc executives and stock owners

Catalyst Biosciences Inc executives and other stock owners filed with the SEC include: